Pre-excitation syndrome: Difference between revisions

Jump to navigation Jump to search
Line 3: Line 3:
{{CMG}} {{AE}} {{Shivam Singla}}
{{CMG}} {{AE}} {{Shivam Singla}}


{{SK}} Pre Excitation Syndromes; Lown-Ganong-Levine Syndrome; Pre-Excitation, Mahaim-Type; Wolff-Parkinson-White Syndrome
{{SK}} Pre Excitation [[Syndromes]]; [[Lown-Ganong-Levine syndrome|Lown-Ganong-Levine Syndrome]]; Pre-Excitation, [[Mahaim type preexcitation|Mahaim-Type]]; [[Wolff-Parkinson-White syndrome|Wolff-Parkinson-White Syndrome]]


==Overview==
==Overview==
Line 9: Line 9:


==Historical Perspective==
==Historical Perspective==
*In 1915, [[Frank Norman Wilson]] became the first to describe the [[condition]] which would later be referred to as [[Wolff–Parkinson–White syndrome]].
*In 1915, [[Frank Norman Wilson]] became the first to describe the [[condition]] which would later be referred to as [[Wolff–Parkinson–White syndrome]].
*In 1930, [[WPW syndrome]] was first described and named after [[John Parkinson]], [[Paul Dudley White]], and [[Louis Wolff]]. They successfully interpreted a series of 11 [[healthy]] young [[patients]] who had repeated attacks of [[tachycardia]] in the presence of [[short PR interval]] and [[bundle branch block]] pattern on the [[ECG]] findings. They also found the [[Association (statistics)|association]] of [[WPW]] with increasing the [[risk]] of [[sudden cardiac death]].<ref>https://doi.org/10.1016/j.eupc.2004.09.005</ref>
*In 1930, [[WPW syndrome]] was first described and named after [[John Parkinson]], [[Paul Dudley White]], and [[Louis Wolff]]. They successfully interpreted a series of 11 [[healthy]] young [[patients]] who had repeated attacks of [[tachycardia]] in the presence of [[short PR interval]] and [[bundle branch block]] pattern on the [[ECG]] findings. They also found the [[Association (statistics)|association]] of [[WPW]] with increasing the [[risk]] of [[sudden cardiac death]].<ref>https://doi.org/10.1016/j.eupc.2004.09.005</ref>
Line 16: Line 17:


==Classification==
==Classification==
*Based on the [[Conduction System|conduction]] pathway or [[fiber]] subtype, [[ pre-excitation syndrome]] may be [[Classification|classified]] into the following sub-types:<ref name="pmid1111564">{{cite journal |vauthors=Lowe KG, Emslie-Smith D, Ward C, Watson H |title=Classification of ventricular pre-excitation. Vectorcardiographic study |journal=Br Heart J |volume=37 |issue=1 |pages=9–19 |date=January 1975 |pmid=1111564 |pmc=484149 |doi=10.1136/hrt.37.1.9 |url=}}</ref><ref name="pmid14563598">{{cite journal| author=Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14563598  }} </ref>
*Based on the [[Conduction System|conduction]] pathway or [[fiber]] subtype, [[ pre-excitation syndrome]] may be [[Classification|classified]] into the following sub-types:<ref name="pmid1111564">{{cite journal |vauthors=Lowe KG, Emslie-Smith D, Ward C, Watson H |title=Classification of ventricular pre-excitation. Vectorcardiographic study |journal=Br Heart J |volume=37 |issue=1 |pages=9–19 |date=January 1975 |pmid=1111564 |pmc=484149 |doi=10.1136/hrt.37.1.9 |url=}}</ref><ref name="pmid14563598">{{cite journal| author=Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ et al.| title=ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2003 | volume= 42 | issue= 8 | pages= 1493-531 | pmid=14563598 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14563598  }} </ref>


Line 45: Line 47:


*Based on their [[conduction]] properties, three types of [[accessory pathways]] are there:<ref name="pmid4561817">{{cite journal |vauthors=Kuramoto K, Matsushita S |title=[Classification and interpretation of WPW syndrome] |language=Japanese |journal=Nippon Rinsho |volume=30 |issue=8 |pages=1770–8 |date=August 1972 |pmid=4561817 |doi= |url=}}</ref>
*Based on their [[conduction]] properties, three types of [[accessory pathways]] are there:<ref name="pmid4561817">{{cite journal |vauthors=Kuramoto K, Matsushita S |title=[Classification and interpretation of WPW syndrome] |language=Japanese |journal=Nippon Rinsho |volume=30 |issue=8 |pages=1770–8 |date=August 1972 |pmid=4561817 |doi= |url=}}</ref>
#[[Accessory pathway|Manifest Accessory Pathways]]: [[Conducts]] more rapidly as compared to [[AV nodal conduction]]. [[Delta waves]] are commonly seen in [[ECG]].
#[[Accessory pathway|Manifest Accessory Pathways]]: [[Conducts]] more rapidly as compared to [[AV nodal conduction]]. [[Delta waves]] are commonly seen in [[ECG]].
#[[Concealed]] [[Accessory Pathways]]: [[Conducts]] in the [[retrograde direction]]. As its name represents, the changes in [[ECG]] are [[concealed]] and no [[delta waves]] are seen.
#[[Concealed]] [[Accessory Pathways]]: [[Conducts]] in the [[retrograde direction]]. As its name represents, the changes in [[ECG]] are [[concealed]] and no [[delta waves]] are seen.
Line 51: Line 54:
==Pathophysiology==
==Pathophysiology==
===Normal electrical conduction pathway of heart===
===Normal electrical conduction pathway of heart===
*Normally, the [[electrical]] activity of the [[heart]] starts from [[SA node]].
*Normally, the [[electrical]] activity of the [[heart]] starts from [[SA node]].
*The [[impulse]] generation usually happens in the right [[atrium]] near the [[entrance]] of [[superior vena cava]] and it travels from [[SA node]] to the [[AV node]].
*The [[impulse]] generation usually happens in the right [[atrium]] near the [[entrance]] of [[superior vena cava]] and it travels from [[SA node]] to the [[AV node]].
Line 57: Line 61:


===Pre-excitation pathway===
===Pre-excitation pathway===
*[[WPW]] is another word for [[pre-excitation]] of the [[ventricle]] through the [[accessory]] [[pathway]] instead of going through the usual pathway of [[AV node]] which usually slows down the [[speed]] of [[conduction]] of [[impulses]] transmitting to [[ventricles]].
*[[WPW]] is another word for [[pre-excitation]] of the [[ventricle]] through the [[accessory]] [[pathway]] instead of going through the usual pathway of [[AV node]] which usually slows down the [[speed]] of [[conduction]] of [[impulses]] transmitting to [[ventricles]].
*The [[accessory]] pathway creates a channel directly to [[conduct]] the [[impulses]] to [[ventricles]] resulting in [[premature]] [[excitation]].
*The [[accessory]] pathway creates a channel directly to [[conduct]] the [[impulses]] to [[ventricles]] resulting in [[premature]] [[excitation]].
Line 257: Line 262:
*[[Tuberous sclerosis]]
*[[Tuberous sclerosis]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Ventricular fibrillation|Ventricular Fibrillation]] (VF)'''<ref name="pmid20142817">{{cite journal |vauthors=Adabag AS, Luepker RV, Roger VL, Gersh BJ |title=Sudden cardiac death: epidemiology and risk factors |journal=Nat Rev Cardiol |volume=7 |issue=4 |pages=216–25 |date=April 2010 |pmid=20142817 |pmc=5014372 |doi=10.1038/nrcardio.2010.3 |url=}}</ref><ref name="pmid27899944">{{cite journal |vauthors=Glinge C, Sattler S, Jabbari R, Tfelt-Hansen J |title=Epidemiology and genetics of ventricular fibrillation during acute myocardial infarction |journal=J Geriatr Cardiol |volume=13 |issue=9 |pages=789–797 |date=September 2016 |pmid=27899944 |pmc=5122505 |doi=10.11909/j.issn.1671-5411.2016.09.006 |url=}}</ref><ref name="pmid11334828">{{cite journal |vauthors=Samie FH, Jalife J |title=Mechanisms underlying ventricular tachycardia and its transition to ventricular fibrillation in the structurally normal heart |journal=Cardiovasc. Res. |volume=50 |issue=2 |pages=242–50 |date=May 2001 |pmid=11334828 |doi=10.1016/s0008-6363(00)00289-3 |url=}}</ref>  
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''[[Ventricular fibrillation|Ventricular Fibrillation]] (VF)'''<ref name="pmid20142817">{{cite journal |vauthors=Adabag AS, Luepker RV, Roger VL, Gersh BJ |title=Sudden cardiac death: epidemiology and risk factors |journal=Nat Rev Cardiol |volume=7 |issue=4 |pages=216–25 |date=April 2010 |pmid=20142817 |pmc=5014372 |doi=10.1038/nrcardio.2010.3 |url=}}</ref><ref name="pmid27899944">{{cite journal |vauthors=Glinge C, Sattler S, Jabbari R, Tfelt-Hansen J |title=Epidemiology and genetics of ventricular fibrillation during acute myocardial infarction |journal=J Geriatr Cardiol |volume=13 |issue=9 |pages=789–797 |date=September 2016 |pmid=27899944 |pmc=5122505 |doi=10.11909/j.issn.1671-5411.2016.09.006 |url=}}</ref><ref name="pmid11334828">{{cite journal |vauthors=Samie FH, Jalife J |title=Mechanisms underlying ventricular tachycardia and its transition to ventricular fibrillation in the structurally normal heart |journal=Cardiovasc. Res. |volume=50 |issue=2 |pages=242–50 |date=May 2001 |pmid=11334828 |doi=10.1016/s0008-6363(00)00289-3 |url=}}</ref>
|
|
*Irregular
*Irregular
Line 319: Line 324:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
*[[WPW]] is commonly found with an [[incidence]] of around 0.1-3.0 per thousand [[population]].<ref name="pmid22579340">{{cite journal |vauthors=Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE |title=PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume=9 |issue=6 |pages=1006–24 |date=June 2012 |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050 |url=}}</ref>
*[[WPW]] is commonly found with an [[incidence]] of around 0.1-3.0 per thousand [[population]].<ref name="pmid22579340">{{cite journal |vauthors=Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE |title=PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume=9 |issue=6 |pages=1006–24 |date=June 2012 |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050 |url=}}</ref>
*More common in the [[male]] [[population]] as compared to [[females]].
*More common in the [[male]] [[population]] as compared to [[females]].
Line 326: Line 332:


==Risk Factors==
==Risk Factors==
*High-risk [[population]] for development of [[atrial fibrillation]] or [[sudden cardiac death]] include:<ref name="pmid22532593">{{cite journal |vauthors=Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes AC, Yee R, Gula LJ, Klein GJ |title=Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis |journal=Circulation |volume=125 |issue=19 |pages=2308–15 |date=May 2012 |pmid=22532593 |doi=10.1161/CIRCULATIONAHA.111.055350 |url=}}</ref>
*High-risk [[population]] for development of [[atrial fibrillation]] or [[sudden cardiac death]] include:<ref name="pmid22532593">{{cite journal |vauthors=Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes AC, Yee R, Gula LJ, Klein GJ |title=Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis |journal=Circulation |volume=125 |issue=19 |pages=2308–15 |date=May 2012 |pmid=22532593 |doi=10.1161/CIRCULATIONAHA.111.055350 |url=}}</ref>
**[[Pilots]]
**[[Pilots]]
Line 338: Line 345:
==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
===Natural History===
===Natural History===
*There are a lot of [[studies]] being done in the [[past]] to [[describe]] the [[natural history]] or [[disease]] course of [[pre-excitation syndrome]]. But data from a recent study- "[[Long term]] [[natural]] [[history]] of [[patients]] with [[WPW]] treated with or without [[catheter ablation]]" showed promising [[results]] in explaining the reduced [[long-term]] [[mortality]] rates in [[WPW]] patients who are matched for [[age]] and [[gender]]. Also explained the lower [[mortality]] rates in [[catheter]] ablated [[patients]] as compared to non ablated ones. Although the [[patients]] can die with [[sudden cardiac death]] but the rate of this scenaio is very less and not commonly observed.<ref name="pmid22532593">{{cite journal |vauthors=Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes AC, Yee R, Gula LJ, Klein GJ |title=Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis |journal=Circulation |volume=125 |issue=19 |pages=2308–15 |date=May 2012 |pmid=22532593 |doi=10.1161/CIRCULATIONAHA.111.055350 |url=}}</ref>
*There are a lot of [[studies]] being done in the [[past]] to [[describe]] the [[natural history]] or [[disease]] course of [[pre-excitation syndrome]]. But data from a recent study- "[[Long term]] [[natural]] [[history]] of [[patients]] with [[WPW]] treated with or without [[catheter ablation]]" showed promising [[results]] in explaining the reduced [[long-term]] [[mortality]] rates in [[WPW]] patients who are matched for [[age]] and [[gender]]. Also explained the lower [[mortality]] rates in [[catheter]] ablated [[patients]] as compared to non ablated ones. Although the [[patients]] can die with [[sudden cardiac death]] but the rate of this scenaio is very less and not commonly observed.<ref name="pmid22532593">{{cite journal |vauthors=Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes AC, Yee R, Gula LJ, Klein GJ |title=Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis |journal=Circulation |volume=125 |issue=19 |pages=2308–15 |date=May 2012 |pmid=22532593 |doi=10.1161/CIRCULATIONAHA.111.055350 |url=}}</ref>


===Complications===
===Complications===
*Most common [[complications]] studied in patients having [[accessory pathway]] [[Conduction basics|conduction]] are [[arrhythmias]] and [[sudden cardiac death]].
*Most common [[complications]] studied in patients having [[accessory pathway]] [[Conduction basics|conduction]] are [[arrhythmias]] and [[sudden cardiac death]].
**[[Tachyarrhythmias]]:
**[[Tachyarrhythmias]]:
Line 350: Line 359:


===Prognosis===
===Prognosis===
*[[Prognosis]] is usually very good till the time patient is getting managed and treated appropriately.
*[[Prognosis]] is usually very good till the time patient is getting managed and treated appropriately.
*[[Catheter ablation]] showed promising results in the [[curative]] [[treatment]] of [[patients]] suffering from this [[disorder]].
*[[Catheter ablation]] showed promising results in the [[curative]] [[treatment]] of [[patients]] suffering from this [[disorder]].
Line 358: Line 368:
==Diagnosis==
==Diagnosis==
===WPW Syndrome===
===WPW Syndrome===
*[[WPW syndrome]] is a combination of [[WPW]] pattern on [[ECG]] + [[Paroxysmal arrhythmias]]. The [[accessory pathways]] are usually named as [[Bundle of Kent]] or [[AV]] [[bypass tracts]].
*[[WPW syndrome]] is a combination of [[WPW]] pattern on [[ECG]] + [[Paroxysmal arrhythmias]]. The [[accessory pathways]] are usually named as [[Bundle of Kent]] or [[AV]] [[bypass tracts]].
*[[ECG]] features of [[WPW]] syndrome are:
*[[ECG]] features of [[WPW]] syndrome are:
Line 373: Line 384:


===Lown-Ganong-Levine(LGL) Syndrome===
===Lown-Ganong-Levine(LGL) Syndrome===
*The [[accessory pathways]] here are named as [[James fibers]], also known as [[atrionodal fibers]] connecting the [[Atrium (heart)|atrium]] to the distal [[Atrioventricular node|AV node]]. These usually [[conduct]] the [[impulses]] from [[atria]] to the initial portion of the [[AV node]].
*The [[accessory pathways]] here are named as [[James fibers]], also known as [[atrionodal fibers]] connecting the [[Atrium (heart)|atrium]] to the distal [[Atrioventricular node|AV node]]. These usually [[conduct]] the [[impulses]] from [[atria]] to the initial portion of the [[AV node]].
*[[ECG]] features:
*[[ECG]] features:
Line 381: Line 393:


===Mahaim-Type Pre-excitation===
===Mahaim-Type Pre-excitation===
*The [[accessory pathways]] named as [[Mahaim fibers]] connect the [[Atrium (heart)|Atrium]], [[AV node]], or [[bundle of His]] to the [[Purkinje fibers]] or [[ventricular myocardium]].<ref name="pmid15489095">{{cite journal |vauthors=Sternick EB, Timmermans C, Sosa E, Cruz FE, Rodriguez LM, Fagundes MA, Gerken LM, Wellens HJ |title=The electrocardiogram during sinus rhythm and tachycardia in patients with Mahaim fibers: the importance of an "rS" pattern in lead III |journal=J. Am. Coll. Cardiol. |volume=44 |issue=8 |pages=1626–35 |date=October 2004 |pmid=15489095 |doi=10.1016/j.jacc.2004.07.035 |url=}}</ref>
*The [[accessory pathways]] named as [[Mahaim fibers]] connect the [[Atrium (heart)|Atrium]], [[AV node]], or [[bundle of His]] to the [[Purkinje fibers]] or [[ventricular myocardium]].<ref name="pmid15489095">{{cite journal |vauthors=Sternick EB, Timmermans C, Sosa E, Cruz FE, Rodriguez LM, Fagundes MA, Gerken LM, Wellens HJ |title=The electrocardiogram during sinus rhythm and tachycardia in patients with Mahaim fibers: the importance of an "rS" pattern in lead III |journal=J. Am. Coll. Cardiol. |volume=44 |issue=8 |pages=1626–35 |date=October 2004 |pmid=15489095 |doi=10.1016/j.jacc.2004.07.035 |url=}}</ref>
*[[ECG]] findings are usually normal.
*[[ECG]] findings are usually normal.


===History and Symptoms===
===History and Symptoms===
*People with [[Wolff-Parkinson-White syndrome|Pre- Excitation syndromes]] maybe [[Asymptomatic|asymptomatic,]] however, the individuals commonly experience the following symptoms:
*People with [[Wolff-Parkinson-White syndrome|Pre- Excitation syndromes]] maybe [[Asymptomatic|asymptomatic,]] however, the individuals commonly experience the following symptoms:
**[[Palpitation|Palpitations]]
**[[Palpitation|Palpitations]]
Line 397: Line 411:
==Treatment==
==Treatment==
===Medical Treatment===
===Medical Treatment===
*[[HEMODYNAMICALY]] [[UNSTABLE PATIENT]] --  DIRECT [[Synchronized cardioversion|SYNCHRONIZED CARDIOVERSION]], BIPHASIC ( INITIAL 100 J,  LATER ON- 200J OR 360J).
*[[HEMODYNAMICALY]] [[UNSTABLE PATIENT]] --  DIRECT [[Synchronized cardioversion|SYNCHRONIZED CARDIOVERSION]], BIPHASIC ( INITIAL 100 J,  LATER ON- 200J OR 360J).
*[[HEMODYNAMICALLY]] STABLE [[PATIENTS]]  -- THE FOLLOWING ALGORITHM CAN BE FOLLOWED
*[[HEMODYNAMICALLY]] STABLE [[PATIENTS]]  -- THE FOLLOWING ALGORITHM CAN BE FOLLOWED
====GENERAL PROTOCOL====
====GENERAL PROTOCOL====
General protocol includes the following:<ref name="pmid30056397">{{cite journal |vauthors=Stasiak A, Niewiadomska-Jarosik K, Kędziora P |title=Clinical course and treatment of children and adolescents with the preexcitation syndrome - own studies |journal=Dev Period Med |volume=22 |issue=2 |pages=113–122 |date=2018 |pmid=30056397 |doi= |url=}}</ref>
General protocol includes the following:<ref name="pmid30056397">{{cite journal |vauthors=Stasiak A, Niewiadomska-Jarosik K, Kędziora P |title=Clinical course and treatment of children and adolescents with the preexcitation syndrome - own studies |journal=Dev Period Med |volume=22 |issue=2 |pages=113–122 |date=2018 |pmid=30056397 |doi= |url=}}</ref>
*[[Antiarrhythmic drug]]  
*[[Antiarrhythmic drug]]  
**Helps in slowing the [[accessory pathway]] [[conduction]] and thus plays a major role in the [[Acute|acute events.]]
**Helps in slowing the [[accessory pathway]] [[conduction]] and thus plays a major role in the [[Acute|acute events.]]
Line 413: Line 430:


====IN CASE OF ACUTE [[AVRT]]/[[AVNRT]]====
====IN CASE OF ACUTE [[AVRT]]/[[AVNRT]]====
*Treated by blocking the [[AV nodal]] [[conduction]]  
*Treated by blocking the [[AV nodal]] [[conduction]]  
**Help in blocking the [[Pathways Health and Research Centre|pathways]] responsible for causing [[dysrhythmias]] through the involvement of the [[AV node]] (AVRT/AVNRT).
**Help in blocking the [[Pathways Health and Research Centre|pathways]] responsible for causing [[dysrhythmias]] through the involvement of the [[AV node]] (AVRT/AVNRT).
Line 420: Line 438:


====[[ATRIAL FLUTTER]]/[[FIBRILLATION]]====
====[[ATRIAL FLUTTER]]/[[FIBRILLATION]]====
*If [[wide complex]] [[tachycardia]] is present:<ref name="pmid23545139">{{cite journal |vauthors=Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS |title=Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines |journal=Circulation |volume=127 |issue=18 |pages=1916–26 |date=May 2013 |pmid=23545139 |doi=10.1161/CIR.0b013e318290826d |url=}}</ref>
*If [[wide complex]] [[tachycardia]] is present:<ref name="pmid23545139">{{cite journal |vauthors=Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS |title=Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines |journal=Circulation |volume=127 |issue=18 |pages=1916–26 |date=May 2013 |pmid=23545139 |doi=10.1161/CIR.0b013e318290826d |url=}}</ref>
**Use IV [[Amiodarone]] or [[Procainamaide]]
**Use IV [[Amiodarone]] or [[Procainamaide]]


====RADIOFREQUENCY ABLATION====
====RADIOFREQUENCY ABLATION====
*This modality has replaced [[drug therapy]] and other [[Surgery operation|surgical treatment]] options by showing promising results. Best results are studied these [[days]] when it is used in [[Conjunction introduction|conjunction]] with [[cryoblation]] (commonly used for [[Accessory pathway|septal Accessory pathways]] and for [[accessory pathways]] near small [[coronary arteries]]).<ref name="pmid22579340">{{cite journal |vauthors=Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE |title=PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume=9 |issue=6 |pages=1006–24 |date=June 2012 |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050 |url=}}</ref>
*This modality has replaced [[drug therapy]] and other [[Surgery operation|surgical treatment]] options by showing promising results. Best results are studied these [[days]] when it is used in [[Conjunction introduction|conjunction]] with [[cryoblation]] (commonly used for [[Accessory pathway|septal Accessory pathways]] and for [[accessory pathways]] near small [[coronary arteries]]).<ref name="pmid22579340">{{cite journal |vauthors=Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE |title=PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS) |journal=Heart Rhythm |volume=9 |issue=6 |pages=1006–24 |date=June 2012 |pmid=22579340 |doi=10.1016/j.hrthm.2012.03.050 |url=}}</ref>
*This technique is used widely with best results in:  
*This technique is used widely with best results in:  
Line 436: Line 456:


===Surgical management===
===Surgical management===
*Surgical management includes the following options:
*Surgical management includes the following options:
**[[Endocardial|ENDOCARDIAL]] SURGICAL APPROACH
**[[Endocardial|ENDOCARDIAL]] SURGICAL APPROACH
Line 446: Line 467:


==Prevention==
==Prevention==
*The most common [[preventive]] measures used against [[WPW]] are [[radiofrequency catheter ablation]].  
*The most common [[preventive]] measures used against [[WPW]] are [[radiofrequency catheter ablation]].  
**This [[helps]] in [[preventing]] future attacks by doing the ablation of [[accessory pathways]] with a success rate of >95%.
**This [[helps]] in [[preventing]] future attacks by doing the ablation of [[accessory pathways]] with a success rate of >95%.

Revision as of 21:05, 18 February 2021

Pre-excitation syndrome Microchapters

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Pre-excitation Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Diagnosis

Treatment

Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2] Associate Editor(s)-in-Chief: Shivam Singla, M.D.[3]

Synonyms and keywords: Pre Excitation Syndromes; Lown-Ganong-Levine Syndrome; Pre-Excitation, Mahaim-Type; Wolff-Parkinson-White Syndrome

Overview

Pre-excitation syndrome is a condition in which the ventricles of heart depolarize earlier than expected via some accessory pathway conduction thus, leading to the premature contraction. Normally, atria and ventricles are interconnected with each other via AV node (atrioventricular node). But in all the pre-excitation syndromes, an accessory pathway is present that conducts impulses to ventricles besides the AV node. The accessory pathway passes the electrical impulses to the ventricles before the normal impulse of depolarization passes through the AV node. The phenomenon of depolarizing ventricles through the accessory pathway earlier than the usual depolarization is supposed to happen through the AV node is referred to as "Pre- Excitation". WPW syndrome was described in 1930 and named after John Parkinson, Paul Dudley White, and Louis Wolff. The accessory pathways are named depending upon the regions of atria and ventricles they are connecting such as Bundle of His, Mahaim fibers, and James fibers. The typical ECG findings associated with WPW syndrome are shortened PR interval, widened QRS complex and Delta wave which is a slurring in the upstroke of QRS complex due to preexcitation of ventricles via the accessory pathway. ECG findings along with symptomatic tachyarrhythmias are referred to as Wolff-Parkinson-White syndrome. Although it is more common in the adult, males have an incidence rate of 0.1-0.3 %, WPW can be considered as a congenital anomaly in some cases where it is usually present since the birth and in others, it is considered as a developmental anomaly. Studies have proven its lower prevalence in children aged between 6-13 than those in the age group of 14-15 years of age. Hemodynamically unstable patients should be managed with a direct cardioversion. For the stable patients, medical management should be tried first before going for other acceptable options of catheter ablation or surgical intervention. Although Catheter ablation has widely replaced the surgical option due to its less invasive technique and better outcomes, still in cases where catheter ablation cannot be done or doesn't prove to be effective, the surgical option is worth considering with a curative rate of nearly 100%.

Historical Perspective

WPW Syndrome was given its name in 1930 by Wolf, Parkinson, and White. Source: Ecgpedia.org

Classification

Type Conduction pathway QRS interval PR interval Delta wave
Wolff-Parkinson-White syndrome Bundle of Kent Wide/long Usually short Yes
Lown-Ganong-Levine syndrome "James bundle" (atria to bundle of His) Normal/Unaffected Short No
Mahaim-type Mahaim fibers Long Normal No
  1. Manifest Accessory Pathways: Conducts more rapidly as compared to AV nodal conduction. Delta waves are commonly seen in ECG.
  2. Concealed Accessory Pathways: Conducts in the retrograde direction. As its name represents, the changes in ECG are concealed and no delta waves are seen.
  3. Latent Accessory Pathways: These are located in the lateral part of the heart as compared to AV node. Hence, the impulses are delayed in traveling to the ventricles through the AV node which is at a much shorter distance as compared to the latent fibers located at the farther end.

Pathophysiology

Normal electrical conduction pathway of heart

Pre-excitation pathway

Differentiating Pre-excitation Syndrome from other Diseases

Arrhythmia Rhythm Rate P wave PR Interval QRS Complex Response to Maneuvers Epidemiology Co-existing Conditions
Atrial Fibrillation (AFib)[6][7]
  • Absent
  • Less than 0.12 seconds, consistent, and normal in morphology in the absence of aberrant conduction
  • 2.7–6.1 million people in the United States have AFib
  • 2% of people younger than age 65 have AFib, while about 9% of people aged 65 years or older have AFib
Atrial Flutter[8]
  • 75 (4:1 block), 100 (3:1 block) and 150 (2:1 block) beats per minute (bpm), but 150 is more common
  • Varies depending upon the magnitude of the block, but is short
  • Less than 0.12 seconds, consistent, and normal in morphology
  • Conduction may vary in response to drugs and maneuvers dropping the rate from 150 to 100 or to 75 bpm
Atrioventricular nodal reentry tachycardia (AVNRT)[9][10][11]
  • 140-280 bpm
Multifocal Atrial Tachycardia[12][13]
  • Irregular
  • Atrial rate is > 100 beats per minute
  • Less than 0.12 seconds, consistent, and normal in morphology
Paroxysmal Supraventricular Tachycardia
  • Regular
  • 150 and 240 bpm
  • Absent
  • Hidden in QRS
  • Absent
  • Narrow complexes (< 0.12 s)
Premature Atrial Contractrions (PAC)[14][15]
  • 80-120 bpm
  • Upright
  • Usually narrow (< 0.12 s)
Wolff-Parkinson-White Syndrome[16][17]
  • Regular
  • Atrial rate is nearly 300 bpm and the ventricular rate is at 150 bpm
  • Less than 0.12 seconds
Ventricular Fibrillation (VF)[18][19][20]
  • Irregular
  • 150 to 500 bpm
  • Absent
  • Absent
  • Absent (R on T phenomenon in the setting of ischemia)
Ventricular Tachycardia[21][22]
  • Regular
  • > 100 bpm (150-200 bpm common)
  • Absent
  • Absent
  • Initial R wave in V1, initial r > 40 ms in V1/V2, notched S in V1, initial R in aVR, lead II R wave peak time ≥50 ms, no RS in V1-V6, and atrioventricular dissociation
  • Wide complex, QRS duration > 120 milliseconds
  • 5-10% of patients presenting with AMI

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Natural History

Complications

Prognosis

Diagnosis

WPW Syndrome

WPW ECG changes with significant 1) Delta wave 2) PR interval shortening 3) Wide QRS complexes. [1]

Lown-Ganong-Levine(LGL) Syndrome

Mahaim-Type Pre-excitation

History and Symptoms

Treatment

Medical Treatment

GENERAL PROTOCOL

General protocol includes the following:[26]

IN CASE OF ACUTE AVRT/AVNRT

ATRIAL FLUTTER/FIBRILLATION

RADIOFREQUENCY ABLATION

Class 3 Antiarrhythmics and class IC drugs are used with AV nodal blocking agents in patients with a history of atrial flutter or A.Fib. Sotalol and Flecainide would be the safe options to use in pregnancy.

Surgical management

Prevention

References

  1. https://doi.org/10.1016/j.eupc.2004.09.005
  2. Lowe KG, Emslie-Smith D, Ward C, Watson H (January 1975). "Classification of ventricular pre-excitation. Vectorcardiographic study". Br Heart J. 37 (1): 9–19. doi:10.1136/hrt.37.1.9. PMC 484149. PMID 1111564.
  3. Blomström-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ; et al. (2003). "ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary. a report of the American college of cardiology/American heart association task force on practice guidelines and the European society of cardiology committee for practice guidelines (writing committee to develop guidelines for the management of patients with supraventricular arrhythmias) developed in collaboration with NASPE-Heart Rhythm Society". J Am Coll Cardiol. 42 (8): 1493–531. PMID 14563598.
  4. Kuramoto K, Matsushita S (August 1972). "[Classification and interpretation of WPW syndrome]". Nippon Rinsho (in Japanese). 30 (8): 1770–8. PMID 4561817.
  5. Moskowitz A, Chen KP, Cooper AZ, Chahin A, Ghassemi MM, Celi LA (October 2017). "Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data". Shock. 48 (4): 436–440. doi:10.1097/SHK.0000000000000869. PMC 5603354. PMID 28328711.
  6. Harris K, Edwards D, Mant J (2012). "How can we best detect atrial fibrillation?". J R Coll Physicians Edinb. 42 Suppl 18: 5–22. doi:10.4997/JRCPE.2012.S02. PMID 22518390.
  7. Lankveld TA, Zeemering S, Crijns HJ, Schotten U (July 2014). "The ECG as a tool to determine atrial fibrillation complexity". Heart. 100 (14): 1077–84. doi:10.1136/heartjnl-2013-305149. PMID 24837984.
  8. Cosío FG (June 2017). "Atrial Flutter, Typical and Atypical: A Review". Arrhythm Electrophysiol Rev. 6 (2): 55–62. doi:10.15420/aer.2017.5.2. PMC 5522718. PMID 28835836.
  9. Letsas KP, Weber R, Siklody CH, Mihas CC, Stockinger J, Blum T, Kalusche D, Arentz T (April 2010). "Electrocardiographic differentiation of common type atrioventricular nodal reentrant tachycardia from atrioventricular reciprocating tachycardia via a concealed accessory pathway". Acta Cardiol. 65 (2): 171–6. doi:10.2143/AC.65.2.2047050. PMID 20458824.
  10. Katritsis DG, Josephson ME (August 2016). "Classification, Electrophysiological Features and Therapy of Atrioventricular Nodal Reentrant Tachycardia". Arrhythm Electrophysiol Rev. 5 (2): 130–5. doi:10.15420/AER.2016.18.2. PMC 5013176. PMID 27617092.
  11. Schernthaner C, Danmayr F, Strohmer B (2014). "Coexistence of atrioventricular nodal reentrant tachycardia with other forms of arrhythmias". Med Princ Pract. 23 (6): 543–50. doi:10.1159/000365418. PMC 5586929. PMID 25196716.
  12. Goodacre S, Irons R (March 2002). "ABC of clinical electrocardiography: Atrial arrhythmias". BMJ. 324 (7337): 594–7. doi:10.1136/bmj.324.7337.594. PMC 1122515. PMID 11884328.
  13. Scher DL, Arsura EL (September 1989). "Multifocal atrial tachycardia: mechanisms, clinical correlates, and treatment". Am. Heart J. 118 (3): 574–80. doi:10.1016/0002-8703(89)90275-5. PMID 2570520.
  14. Strasburger JF, Cheulkar B, Wichman HJ (December 2007). "Perinatal arrhythmias: diagnosis and management". Clin Perinatol. 34 (4): 627–52, vii–viii. doi:10.1016/j.clp.2007.10.002. PMC 3310372. PMID 18063110.
  15. Lin CY, Lin YJ, Chen YY, Chang SL, Lo LW, Chao TF, Chung FP, Hu YF, Chong E, Cheng HM, Tuan TC, Liao JN, Chiou CW, Huang JL, Chen SA (August 2015). "Prognostic Significance of Premature Atrial Complexes Burden in Prediction of Long-Term Outcome". J Am Heart Assoc. 4 (9): e002192. doi:10.1161/JAHA.115.002192. PMC 4599506. PMID 26316525.
  16. Rosner MH, Brady WJ, Kefer MP, Martin ML (November 1999). "Electrocardiography in the patient with the Wolff-Parkinson-White syndrome: diagnostic and initial therapeutic issues". Am J Emerg Med. 17 (7): 705–14. doi:10.1016/s0735-6757(99)90167-5. PMID 10597097.
  17. Rao AL, Salerno JC, Asif IM, Drezner JA (July 2014). "Evaluation and management of wolff-Parkinson-white in athletes". Sports Health. 6 (4): 326–32. doi:10.1177/1941738113509059. PMC 4065555. PMID 24982705.
  18. Adabag AS, Luepker RV, Roger VL, Gersh BJ (April 2010). "Sudden cardiac death: epidemiology and risk factors". Nat Rev Cardiol. 7 (4): 216–25. doi:10.1038/nrcardio.2010.3. PMC 5014372. PMID 20142817.
  19. Glinge C, Sattler S, Jabbari R, Tfelt-Hansen J (September 2016). "Epidemiology and genetics of ventricular fibrillation during acute myocardial infarction". J Geriatr Cardiol. 13 (9): 789–797. doi:10.11909/j.issn.1671-5411.2016.09.006. PMC 5122505. PMID 27899944.
  20. Samie FH, Jalife J (May 2001). "Mechanisms underlying ventricular tachycardia and its transition to ventricular fibrillation in the structurally normal heart". Cardiovasc. Res. 50 (2): 242–50. doi:10.1016/s0008-6363(00)00289-3. PMID 11334828.
  21. Levis JT (2011). "ECG Diagnosis: Monomorphic Ventricular Tachycardia". Perm J. 15 (1): 65. doi:10.7812/tpp/10-130. PMC 3048638. PMID 21505622.
  22. Koplan BA, Stevenson WG (March 2009). "Ventricular tachycardia and sudden cardiac death". Mayo Clin. Proc. 84 (3): 289–97. doi:10.1016/S0025-6196(11)61149-X. PMC 2664600. PMID 19252119.
  23. 23.0 23.1 Cohen MI, Triedman JK, Cannon BC, Davis AM, Drago F, Janousek J, Klein GJ, Law IH, Morady FJ, Paul T, Perry JC, Sanatani S, Tanel RE (June 2012). "PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS)". Heart Rhythm. 9 (6): 1006–24. doi:10.1016/j.hrthm.2012.03.050. PMID 22579340.
  24. 24.0 24.1 Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, Skanes AC, Yee R, Gula LJ, Klein GJ (May 2012). "Risk of arrhythmia and sudden death in patients with asymptomatic preexcitation: a meta-analysis". Circulation. 125 (19): 2308–15. doi:10.1161/CIRCULATIONAHA.111.055350. PMID 22532593.
  25. Sternick EB, Timmermans C, Sosa E, Cruz FE, Rodriguez LM, Fagundes MA, Gerken LM, Wellens HJ (October 2004). "The electrocardiogram during sinus rhythm and tachycardia in patients with Mahaim fibers: the importance of an "rS" pattern in lead III". J. Am. Coll. Cardiol. 44 (8): 1626–35. doi:10.1016/j.jacc.2004.07.035. PMID 15489095.
  26. Stasiak A, Niewiadomska-Jarosik K, Kędziora P (2018). "Clinical course and treatment of children and adolescents with the preexcitation syndrome - own studies". Dev Period Med. 22 (2): 113–122. PMID 30056397.
  27. Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS (May 2013). "Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines". Circulation. 127 (18): 1916–26. doi:10.1161/CIR.0b013e318290826d. PMID 23545139.